# Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

> **NCT07245069** · PHASE2 · RECRUITING · sponsor: **University Medical Centre Ljubljana** · enrollment: 100 (estimated)

## Conditions studied

- Heart Failure
- Anthracycline-induced Cardiac Toxicity
- Endothelial Function (FMD)
- Arterial Stiffness
- Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07245069
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2028-11
- **Final completion:** 2029-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07245069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07245069, "Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07245069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*